Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.53 |
| ▸ | MAOA | P21397 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | CALML3 | P27482 | 1/20 | 0.53 |
| ▸ | SDHA | P31040 | 1/20 | 0.53 |
| ▸ | F10 | P00742 | 13/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5839054 | 0.90 | MAOB (0.56) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL5838375 | 0.90 | F10 (0.47) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL5838147 | 0.88 | CYP2E1 (0.49) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL5838128 | 0.87 | MAOB (0.58) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL5838360 | 0.87 | MAOB (0.54) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL5837798 | 0.86 | MAOA (0.70) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL5839315 | 0.86 | MAOB (0.55) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL5839469 | 0.85 | MAOB (0.58) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL5837869 | 0.85 | MAOB (0.71) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL5839127 | 0.85 | MAOB (0.58) | MAOBMAOALMNAPTGS1CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105547-B2 | Antimicrobial 1-aryl dihydropyridone compounds | PHARMACIA AND UPJOHN COMPANY (US) | 2006-09-12 | — | — | US | claimed |
| US-20050070580-A1 | Antimicrobial 1-aryl dihydropyridone compounds | GORDEEV MIKHAIL FEDOR (US) | 2005-03-31 | — | — | US | claimed |
| US-7105547-B2 | Antimicrobial 1-aryl dihydropyridone compounds | PHARMACIA AND UPJOHN COMPANY (US) | 2006-09-12 | — | — | US | disclosed |
| US-20050070580-A1 | Antimicrobial 1-aryl dihydropyridone compounds | GORDEEV MIKHAIL FEDOR (US) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070580-A1 | Antimicrobial 1-aryl dihydropyridone compounds | TLR1, QDPR, AP1S1 | MAOB 3414/4885MAOA 3032/4885LMNA 4798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.